Iovance Biotherapeutics (IOVA) Net Equity Issued and Repurchased (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Net Equity Issued and Repurchased for 14 consecutive years, with $98.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 33.86% year-over-year to $98.5 million; the TTM figure through Mar 2026 stood at $255.9 million (down 26.54% YoY), while the FY2025 annual figure was $306.3 million, down 22.9% from the prior year.
• Net Equity Issued and Repurchased grew to $98.5 million in Q1 2026 per IOVA's latest filing, from $55.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $260.1 million in Q1 2023 and bottomed at $1000.0 in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $107.8 million across 5 years, with a median of $93.5 million in 2025.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 100.0% — and 2025, when it surged 86.29%.
• Iovance Biotherapeutics' Net Equity Issued and Repurchased stood at $189.5 million in 2022, then slumped by 100.0% to $1000.0 in 2023, then surged by 4751700.0% to $47.5 million in 2024, then rose by 17.38% to $55.8 million in 2025, then surged by 76.62% to $98.5 million in 2026.
• Business Quant data shows IOVA's Net Equity Issued and Repurchased at $98.5 million in Q1 2026, $55.8 million in Q4 2025, and $88.5 million in Q3 2025.